Advanced Glycation End-Products-, C-Type Lectin- and Cysteinyl/ Leukotriene-Receptors in Distinct Mesenchymal Stromal Cell Populations: Differential Transcriptional Profiles in Response to Inflammation

Document Type : Original Article

Authors

1 Laboratory of Clinical Cell Therapy, Institute of Jules Bordet, Brussels, Free University of Brussels (ULB), Brussels, Belgium

2 Institute of Molecular Biology and Medicine, Free University of Brussels, Gosselies, Belgium

3 Laboratory of Cancer Biology and Molecular Immunology, Faculty of Sciences I, Lebanese University, Hadath, Lebanon

4 Laboratory of Clinical Cell Therapy, Institute of Jules Bordet, Brussels, Free University of Brussels (ULB), Brussels, Belgium;4Experimental Hematology, Institute of Jules Bordet, Free University of Brussels, Waterloo Street, Brus

Abstract

Objective
We aimed at characterizing the transcription profiles of immunological receptors associated with the biology of mesenchymal stromal cells (MSCs).
Materials and Methods
In this experimental study, quantitative real time-polymerase chain reaction (qRT- PCR) was performed to establish the transcription profiles of advanced glycation end-products (RAGE) receptor, C-type lectin receptors (CLRs, including DECTIN-1, DECTIN-2 and MINCLE), leukotriene B4 (LTB4) receptors (BLT1 and BLT2) and cysteinyl leukotrienes (CysLTs) receptors (CYSLTR1 and CYSLTR2) in distinct populations of MSCs grown under basic or inflammatory conditions.
Results
MSCs derived from adipose tissue (AT), foreskin (FSK), Wharton’s jelly (WJ) and bone marrow (BM) exhibited significantly different transcription levels for these genes. Interestingly, these transcription profiles substantially changed following exposure of MSCs to inflammatory signals.
Conclusion
Collectively, for the first time, our data highlights that MSCs depending on their tissue-source, present several relevant receptors potentially involved in the regulation of inflammatory and immunological responses. Understanding the roles of these receptors within MSCs immunobiology will incontestably improve the efficiency of utilization of MSCs during cell-based therapies.

Keywords